WAM
CNCE

Wealthspire Advisors (Maryland)’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$4K – 2245
2019
Q1 		$4K Hold
300
– – ﹤0.01% 1947
2018
Q4 		$4K Hold
300
– – ﹤0.01% 1881
2018
Q3 		$4K Hold
300
– – ﹤0.01% 1958
2018
Q2 		$5K Hold
300
– – ﹤0.01% 1831
2018
Q1 		$7K Buy
+300
New +$6.67K ﹤0.01% 1704

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CNCE Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 300 shares — an estimated $4K sold.

Wealthspire Advisors (Maryland) first reported a position in CNCE in Q1 2018 and held it in 5 quarters. The position peaked at $7K in Q1 2018. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 300 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $4K.
  • Wealthspire Advisors (Maryland) first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 5 quarters.
  • Wealthspire Advisors (Maryland)'s Concert Pharmaceuticals, Inc. position peaked at $7K in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.